ClinicalTrials.gg
CompletedNCT03138512CheckMate 914Updated Dec 18, 2024Results posted

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

A Phase 3 interventional study of nivolumab and ipilimumab in Carcinoma, Renal Cell, sponsored by Bristol-Myers Squibb. Completed at 200 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,641
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.

Enrollment
2nd of 63
1,641 · median 54
Started
2017
with 12 others
Phase 3
8 of 63
1 open now
Registered
30th of 63
by date
Lead sponsor
14 of 63
Bristol-Myers Squibb

Among the 63 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 2nd largest by enrollment, is one of 13 that started in 2017, is one of 8 in phase 3, and was the 30th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

9 of the 63 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing nivolumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether nivolmab alone or the combination of nivolumab and ipilimumab versus placebo, is safe and effective for delaying or preventing recurrence of cancer in participants who have experienced partial or entire removal of a kidney.

Read the detailed description

The study has two primary endpoints. The first primary completion date is anticipated to be reached July 2022 (DFS in Part A). The second primary completion date is anticipated to be reached July 2024 (DFS in Part B).

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • localized
  • resected
  • adjuvant
  • Renal Cell Carcinoma
  • Kidney Cancer
  • Nephrectomy
  • Clear cell
  • High Risk of Relapse/Recurrence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Kidney tumor has been completely resected with negative surgical margins obtained. The randomization must occur greater than 4 weeks and less than (or equal to) 12 weeks from the date of nephrectomy
  • Pathologic tumor, node, and (TNM) staging meeting one of the following: pT2a, G3 or G4, N0 M0; pT2b, G any, N0 M0; pT3, (a, b, c), G any, N0 M0; pT4, G any, N0 M0; pT any, G any, N1 M0
  • Post-nephrectomy tumor shows renal cell cancer (RCC) with a predominantly clear cell histology, including participants with sarcomatoid features
  • Participants must have no clinical or radiological evidence of macroscopic residual disease or distant metastases after nephrectomy
  • (ECOG) Performance Status (PS) 0-1
  • Women must agree to follow methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Participants with an active known or suspected disease
  • Known history of positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Prior treatment with an , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Any severe or serious, acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
  • History of allergy or to study drug components
  • Participants with a condition requiring systemic treatment with
  • Participants who have received a live/attenuated vaccine within 30 days of first treatment

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,641 participants (actual)

Study arms

  • Experimental
    Part A, Arm A: nivolumab + ipilimumab

    Biological: nivolumab · Biological: ipilimumab

  • Placebo comparator
    Part A, Arm B: nivolumab placebo + ipilimumab placebo

    Drug: nivolumab placebo · Drug: ipilimumab placebo

  • Experimental
    Part B, Arm A: nivolumab + ipilimumab

    Biological: nivolumab · Biological: ipilimumab

  • Placebo comparator
    Part B, Arm B: nivolumab placebo + ipilimumab placebo

    Drug: nivolumab placebo · Drug: ipilimumab placebo

  • Experimental
    Part B, Arm C: nivolumab + ipilimumab placebo

    Biological: nivolumab · Drug: ipilimumab placebo

Interventions

  • Biologicalnivolumab

    Specified dose on specified days

    Also known as: Opdivo

  • Biologicalipilimumab

    Specified dose on specified days

    Also known as: Yervoy

  • Drugnivolumab placebo

    Specified dose on specified days

  • Drugipilimumab placebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) by BICR - Treatment Part A and B

    Disease-Free Survival (DFS) is defined as the time from randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary renal cell carcinoma (RCC) primary cancer), distance metastasis, or death, whichever came first per Blinded Independent Central Review (BICR) based on Kaplan-Meier estimates.

    Time frame: From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)

Secondary outcomes

  1. Overall Survival (OS) - Treatment Part A and B

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. Based on Kaplan-Meier estimates.

    Time frame: From randomization to the date of death (up to approximately 72 months)

  2. Overall Survival (OS) Rate (5 Years) - Treatment Part A and B

    Overall survival rate at 5 years is defined as the percentage of participants who are alive at 5 years.

    Time frame: At 5 years

  3. Disease-Free Survival (DFS) Per BICR in Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B

    Disease-Free Survival (DFS) is defined as the time from randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary renal cell carcinoma (RCC) primary cancer), distance metastasis, or death, whichever came first per Blinded Independent Central Review (BICR) based on Kaplan-Meier estimates.

    Time frame: From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)

  4. Overall Survival (OS) in the Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B

    Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. Based on Kaplan-Meier estimates

    Time frame: From randomization to the date of death (up to approximately 72 months)

  5. The Number of Participants With Adverse Events up to 30 Days After Last Dose of Study Therapy - Treatment Part A

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.

    Time frame: From first dose to 30 days post last dose (up to approximately 40 weeks)

  6. The Number of Participants With Adverse Events up to 30 Days After Last Dose of Study Therapy - Treatment Part B

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.

    Time frame: From first dose to 30 days post last dose (up to approximately 40 weeks)

  7. The Number of Participants With Adverse Events up to 100 Days After Last Dose of Study Therapy - Treatment Part A

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.

    Time frame: From first dose to 100 days post last dose (up to approximately 50 weeks)

  8. The Number of Participants With Adverse Events up to 100 Days After Last Dose of Study Therapy - Treatment Part B

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.

    Time frame: From first dose to 100 days post last dose (up to approximately 50 weeks)

  9. The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 30 Days - Treatment Part A

    Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.

    Time frame: From first dose to 30 days post last dose (up to approximately 40 weeks)

  10. The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 30 Days - Treatment Part B

    Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.

    Time frame: From first dose to 30 days post last dose (up to approximately 40 weeks)

  11. The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 100 Days - Treatment Part A

    Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.

    Time frame: From first dose to 100 days post last dose (up to approximately 50 weeks)

  12. The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 100 Days - Treatment Part B

    Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.

    Time frame: From first dose to 100 days post last dose (up to approximately 50 weeks)

07

Results

Posted Dec 18, 2024

Participant flow

Randomization
Participant flow — Randomization
MilestoneTreatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
Started405411206208411
Completed404407204207408
Not completed14213
Withdrew: Participants withdrew consent01100
Withdrew: Participant no longer meets study criteria03113
Withdrew: Other reasons10000
Treatment Part A
Participant flow — Treatment Part A
MilestoneTreatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
Started404407000
Completed229360000
Not completed17547000
Withdrew: Disease recurrence1020000
Withdrew: Study drug toxicity1325000
Withdrew: Death10000
Withdrew: Adverse event unrelated to study drug94000
Withdrew: Participant request to discontinue treatment94000
Withdrew: Participant withdrew consent24000
Withdrew: Lost to follow-up01000
Withdrew: Poor/non-compliance10000
Withdrew: Pregnancy01000
Withdrew: Other reasons118000
Treatment Part B
Participant flow — Treatment Part B
MilestoneTreatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
Started00204207408
Completed00118182327
Not completed00862581
Withdrew: Disease recurrence0061210
Withdrew: Study drug toxicity0063345
Withdrew: Death00100
Withdrew: Adverse event unrelated to study drug005212
Withdrew: Participants request to discontinue study treatment00646
Withdrew: Participant withdrew consent00112
Withdrew: Lost to follow-up00010
Withdrew: Poor/non-compliance00111
Withdrew: Other reasons00315

Outcome measures

PrimaryDisease-Free Survival (DFS) by BICR - Treatment Part A and B

Disease-Free Survival (DFS) is defined as the time from randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary renal cell carcinoma (RCC) primary cancer), distance metastasis, or death, whichever came first per Blinded Independent Central Review (BICR) based on Kaplan-Meier estimates.

Time frame:
From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)
Reported as:
Median · Months
Disease-Free Survival (DFS) by BICR - Treatment Part A and B
MonthsTreatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
Disease-Free Survival (DFS) by BICR - Treatment Part A and BNA (NA to NA)NA (65.58 to NA)—NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Treatment Part A: Nivo + Ipi vs Treatment Part A: Placebo · Log Rank · p = 0.6676 · Cox proportional hazard: 0.95 · 95% CI 0.75 to 1.20
  • Treatment Part A: Placebo vs Treatment Part B: Nivo · Log Rank · p = 0.6556 · Cox proportional hazard: 0.93 · 95% CI 0.67 to 1.28
SecondaryOverall Survival (OS) - Treatment Part A and B

Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. Based on Kaplan-Meier estimates.

Time frame:
From randomization to the date of death (up to approximately 72 months)
Reported as:
Median · Months
Overall Survival (OS) - Treatment Part A and B
MonthsTreatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
Overall Survival (OS) - Treatment Part A and BNA (NA to NA)NA (NA to NA)—NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Treatment Part A: Nivo + Ipi vs Treatment Part A: Placebo · Log Rank · p = 0.2436 · Cox proportional hazard: 1.26 · 95% CI 0.85 to 1.85
  • Treatment Part A: Placebo vs Treatment Part B: Nivo · Log Rank · p = 0.4500 · Cox proportional hazard: 1.36 · 95% CI 0.61 to 3.07
SecondaryOverall Survival (OS) Rate (5 Years) - Treatment Part A and B

Overall survival rate at 5 years is defined as the percentage of participants who are alive at 5 years.

Time frame:
At 5 years
Reported as:
Number · Percent of participants
Overall Survival (OS) Rate (5 Years) - Treatment Part A and B
Percent of participantsTreatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
Overall Survival (OS) Rate (5 Years) - Treatment Part A and B85.0 (80.8 to 88.3)87.2 (82.8 to 90.5)———
SecondaryDisease-Free Survival (DFS) Per BICR in Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B

Disease-Free Survival (DFS) is defined as the time from randomization to development of local disease recurrence (ie, recurrence of primary tumor in situ or occurrence of a secondary renal cell carcinoma (RCC) primary cancer), distance metastasis, or death, whichever came first per Blinded Independent Central Review (BICR) based on Kaplan-Meier estimates.

Time frame:
From randomization to development of local disease recurrence, distance metastasis, or death, whichever came first (up to approximately 72 months)
Reported as:
Median · Months
Disease-Free Survival (DFS) Per BICR in Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B
MonthsTreatment Part B: Nivo + IpiTreatment Part B: Nivo
Disease-Free Survival (DFS) Per BICR in Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part BNA (36.17 to NA)NA (NA to NA)
Statistical analysis
  • Treatment Part B: Nivo + Ipi vs Treatment Part B: Nivo · Cox proportional hazard: 1.22 · 95% CI 0.89 to 1.67
SecondaryOverall Survival (OS) in the Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B

Overall Survival (OS) is defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS will be censored on the last date the participants was known to be alive. Based on Kaplan-Meier estimates

Time frame:
From randomization to the date of death (up to approximately 72 months)
Reported as:
Median · Months
Overall Survival (OS) in the Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part B
MonthsTreatment Part B: Nivo + IpiTreatment Part B: Nivo
Overall Survival (OS) in the Contemporaneously Randomized Combination and Monotherapy Participants - Treatment Part BNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Treatment Part B: Nivo + Ipi vs Treatment Part B: Nivo · Cox proportional hazard: 0.75 · 95% CI 0.33 to 1.68
SecondaryThe Number of Participants With Adverse Events up to 30 Days After Last Dose of Study Therapy - Treatment Part A

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.

Time frame:
From first dose to 30 days post last dose (up to approximately 40 weeks)
Reported as:
Count of participants · Participants
The Number of Participants With Adverse Events up to 30 Days After Last Dose of Study Therapy - Treatment Part A
ParticipantsTreatment Part A: Nivo + IpiTreatment Part A: Placebo
Any Grade AE392362
Grade 3-4 AE15444
Grade 5 AE10
Any Grade Drug-Related AE359230
Grade 3-4 Drug-Related AE1148
Grade 5 Drug-Related AE00
SecondaryThe Number of Participants With Adverse Events up to 30 Days After Last Dose of Study Therapy - Treatment Part B

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.

Time frame:
From first dose to 30 days post last dose (up to approximately 40 weeks)
Reported as:
Count of participants · Participants
The Number of Participants With Adverse Events up to 30 Days After Last Dose of Study Therapy - Treatment Part B
ParticipantsTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
Any Grade AE193182362
Grade 3-4 AE593170
Grade 5 AE110
Any Grade Drug-Related AE173107297
Grade 3-4 Drug-Related AE41436
Grade 5 Drug-Related AE000
SecondaryThe Number of Participants With Adverse Events up to 100 Days After Last Dose of Study Therapy - Treatment Part A

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.

Time frame:
From first dose to 100 days post last dose (up to approximately 50 weeks)
Reported as:
Count of participants · Participants
The Number of Participants With Adverse Events up to 100 Days After Last Dose of Study Therapy - Treatment Part A
ParticipantsTreatment Part A: Nivo + IpiTreatment Part A: Placebo
Any Grade AE393365
Grade 3-4 AE16752
Grade 5 AE41
Any Grade Drug-Related AE361230
Grade 3-4 Drug-Related AE1289
Grade 5 Drug-Related AE20
SecondaryThe Number of Participants With Adverse Events up to 100 Days After Last Dose of Study Therapy - Treatment Part B

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Graded according to NCI CTCAE (Version 4) guidelines where grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening, grade 5 = death.

Time frame:
From first dose to 100 days post last dose (up to approximately 50 weeks)
Reported as:
Count of participants · Participants
The Number of Participants With Adverse Events up to 100 Days After Last Dose of Study Therapy - Treatment Part B
ParticipantsTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
Any Grade AE196182367
Grade 3-4 AE683285
Grade 5 AE522
Any Grade Drug-Related AE175108300
Grade 3-4 Drug-Related AE46546
Grade 5 Drug-Related AE000
SecondaryThe Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 30 Days - Treatment Part A

Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.

Time frame:
From first dose to 30 days post last dose (up to approximately 40 weeks)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 30 Days - Treatment Part A
ParticipantsTreatment Part A: Nivo + IpiTreatment Part A: Placebo
HEMOGLOBIN11
PLATELET COUNT10
LEUKOCYTES, LOCAL LAB00
LYMPHOCYTES (ABSOLUTE), TOTAL63
ABSOLUTE NEUTROPHIL COUNT20
ALKALINE PHOSPHATASE, LOCAL LAB30
ASPARTATE AMINOTRANSFERASE, LOCAL LAB143
ALANINE AMINOTRANSFERASE, LOCAL LAB165
BILIRUBIN, TOTAL, LOCAL LAB10
CREATININE, LOCAL LAB11
HYPERNATREMIA00
HYPONATREMIA287
HYPERKALEMIA65
HYPOKALEMIA31
HYPERCALCEMIA30
HYPOCALCEMIA10
HYPERMAGNESEMIA11
HYPOMAGNESEMIA10
HYPERGLYCEMIA61
HYPOGLYCEMIA10
SecondaryThe Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 30 Days - Treatment Part B

Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.

Time frame:
From first dose to 30 days post last dose (up to approximately 40 weeks)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 30 Days - Treatment Part B
ParticipantsTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
HEMOGLOBIN030
PLATELET COUNT010
LEUKOCYTES, LOCAL LAB001
LYMPHOCYTES (ABSOLUTE), TOTAL314
ABSOLUTE NEUTROPHIL COUNT001
ALKALINE PHOSPHATASE, LOCAL LAB110
ASPARTATE AMINOTRANSFERASE, LOCAL LAB445
ALANINE AMINOTRANSFERASE, LOCAL LAB738
BILIRUBIN, TOTAL, LOCAL LAB010
CREATININE, LOCAL LAB300
HYPERNATREMIA000
HYPONATREMIA1119
HYPERKALEMIA122
HYPOKALEMIA110
HYPERCALCEMIA101
HYPOCALCEMIA010
HYPERMAGNESEMIA223
HYPOMAGNESEMIA011
HYPERGLYCEMIA313
HYPOGLYCEMIA001
SecondaryThe Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 100 Days - Treatment Part A

Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.

Time frame:
From first dose to 100 days post last dose (up to approximately 50 weeks)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 100 Days - Treatment Part A
ParticipantsTreatment Part A: Nivo + IpiTreatment Part A: Placebo
HEMOGLOBIN11
PLATELET COUNT10
LEUKOCYTES, LOCAL LAB00
LYMPHOCYTES (ABSOLUTE), TOTAL113
ABSOLUTE NEUTROPHIL COUNT20
ALKALINE PHOSPHATASE, LOCAL LAB50
ASPARTATE AMINOTRANSFERASE, LOCAL LAB173
ALANINE AMINOTRANSFERASE, LOCAL LAB206
BILIRUBIN, TOTAL, LOCAL LAB30
CREATININE, LOCAL LAB41
HYPERNATREMIA00
HYPONATREMIA307
HYPERKALEMIA65
HYPOKALEMIA51
HYPERCALCEMIA30
HYPOCALCEMIA10
HYPERMAGNESEMIA11
HYPOMAGNESEMIA10
HYPERGLYCEMIA71
HYPOGLYCEMIA10
SecondaryThe Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 100 Days - Treatment Part B

Graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE, Version 4.0\] where grade 3 = severe, and grade 4 = life-threatening. Baseline evaluations are defined as evaluations or events that occur before the date and time of the first dose of study treatment.

Time frame:
From first dose to 100 days post last dose (up to approximately 50 weeks)
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Laboratory Parameters by Worst CTC (Grade 3-4) That Worsened Relative to Baseline up to 100 Days - Treatment Part B
ParticipantsTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: Nivo
HEMOGLOBIN231
PLATELET COUNT010
LEUKOCYTES, LOCAL LAB002
LYMPHOCYTES (ABSOLUTE), TOTAL327
ABSOLUTE NEUTROPHIL COUNT002
ALKALINE PHOSPHATASE, LOCAL LAB210
ASPARTATE AMINOTRANSFERASE, LOCAL LAB646
ALANINE AMINOTRANSFERASE, LOCAL LAB9310
BILIRUBIN, TOTAL, LOCAL LAB010
CREATININE, LOCAL LAB403
HYPERNATREMIA000
HYPONATREMIA12113
HYPERKALEMIA124
HYPOKALEMIA122
HYPERCALCEMIA101
HYPOCALCEMIA011
HYPERMAGNESEMIA323
HYPOMAGNESEMIA011
HYPERGLYCEMIA314
HYPOGLYCEMIA001

Adverse events

Collected over All-cause mortality was assessed from a participants first dose to their study completion (up to approximately 72 months) SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 50 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Part A and B: Nivo + Ipi65/611 (10.6%)196/608 (32.2%)544/608 (89.5%)
Treatment Part A and B: Placebo55/619 (8.9%)49/614 (8%)469/614 (76.4%)
Treatment Part B: Nivo22/411 (5.4%)56/408 (13.7%)325/408 (79.7%)
Most frequent serious events
Showing 10 of 219
Most frequent serious events
EventTreatment Part A and B: Nivo + IpiTreatment Part A and B: PlaceboTreatment Part B: Nivo
Adrenal insufficiencyEndocrine disorders21/6080/6143/408
DiarrhoeaGastrointestinal disorders16/6081/6140/408
Acute kidney injuryRenal and urinary disorders13/6081/6142/408
HypophysitisEndocrine disorders12/6080/6140/408
ColitisGastrointestinal disorders12/6080/6141/408
PneumonitisRespiratory, thoracic and mediastinal disorders7/6081/6144/408
Immune-mediated enterocolitisGastrointestinal disorders6/6080/6140/408
PneumoniaInfections and infestations6/6081/6141/408
HyponatraemiaMetabolism and nutrition disorders6/6080/6142/408
VomitingGastrointestinal disorders5/6080/6140/408
Most frequent other events
Showing 10 of 33
Most frequent other events
EventTreatment Part A and B: Nivo + IpiTreatment Part A and B: PlaceboTreatment Part B: Nivo
PruritusSkin and subcutaneous tissue disorders213/608103/614103/408
FatigueGeneral disorders189/608158/61499/408
DiarrhoeaGastrointestinal disorders180/608120/61477/408
HypothyroidismEndocrine disorders131/60828/61454/408
RashSkin and subcutaneous tissue disorders131/60857/61450/408
ArthralgiaMusculoskeletal and connective tissue disorders111/60897/61458/408
NauseaGastrointestinal disorders102/60873/61453/408
HeadacheNervous system disorders102/60889/61453/408
HyperthyroidismEndocrine disorders98/6088/61447/408
Blood creatinine increasedInvestigations82/60859/61440/408

Baseline characteristics

Age, Customized
Age, Customized(Participants)Treatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: NivoTotal
< 652933011321372791142
>= 65 AND < 7593916460108416
>= 75 AND < 85191910112382
>= 85000011
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: NivoTotal
Female1191175967106468
Male2862941471413051173
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: NivoTotal
Hispanic or Latino4144263467212
Not Hispanic or Latino1891979379157715
Unknown or Not Reported1751708795187714
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Part A: Nivo + IpiTreatment Part A: PlaceboTreatment Part B: Nivo + IpiTreatment Part B: PlaceboTreatment Part B: NivoTotal
American Indian or Alaska Native03531425
Asian9365202650254
Native Hawaiian or Other Pacific Islander010001
Black or African American3601414
White3033221731693311298
More than one race000000
Unknown or Not Reported614891249
08

Study locations

200 sites
  • Local Institution - 0019
    Birmingham, Alabama 35205, United States
  • Local Institution - 0056
    Springdale, Arkansas 72762, United States
  • Local Institution - 0186
    Los Angeles, California 90048, United States
  • Local Institution - 0180
    Los Angeles, California 90095, United States
  • Local Institution - 0002
    San Francisco, California 94115, United States
  • Local Institution - 0185
    Aurora, Colorado 80045, United States
  • Local Institution - 0016
    Athens, Georgia 30607, United States
  • Local Institution - 0005
    Chicago, Illinois 60611, United States
  • Local Institution
    Chicago, Illinois 60612, United States
  • Local Institution - 0006
    Saint Louis, Missouri 63110, United States
  • Local Institution - 0012
    Howell, New Jersey 07731, United States
  • Local Institution - 0007
    Buffalo, New York 14263, United States
  • Local Institution - 0181
    New York, New York 10029, United States
  • Local Institution - 0001
    New York, New York 10065, United States
  • Local Institution - 0008
    Columbus, Ohio 43210, United States
  • Local Institution - 0009
    Portland, Oregon 97213, United States
  • Local Institution - 0010
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0014
    Greenville, South Carolina 29607, United States
  • Local Institution - 0013
    Chattanooga, Tennessee 37404, United States
  • Local Institution - 0183
    Nashville, Tennessee 37212, United States
  • Local Institution - 0057
    Fairfax, Virginia 22031, United States
  • Local Institution - 0178
    Capital Federal, Buenos Aires 1280, Argentina
  • Local Institution - 0126
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1425, Argentina
  • Local Institution - 0203
    Ciudad Autónoma De Buenos Aires, Buenos Aires 1426, Argentina
  • Local Institution - 0095
    Mar Del Plata, Buenos Aires 7600, Argentina
  • Local Institution - 0208
    Mar Del Plata, Buenos Aires B7600FZO, Argentina
  • Local Institution - 0173
    Rio Cuarto, Cordoba 5800, Argentina
  • Local Institution - 0232
    Bariloche, RIO Negro 0, Argentina
  • Local Institution - 0179
    Buenos Aires, C1419AHN, Argentina
  • Local Institution - 0099
    Caba, 1199, Argentina
  • Local Institution - 0096
    Cordoba, 5000, Argentina
  • Local Institution - 0098
    Cordoba, X5004FHP, Argentina
  • Local Institution - 0164
    San Juan, 5402, Argentina
  • Local Institution - 0097
    Tucuman, 4000, Argentina
  • Local Institution - 0215
    Macquarie Park, New South Wales 2109, Australia
  • Local Institution - 0032
    Northmead, New South Wales 2152, Australia
  • Local Institution - 0036
    Randwick, New South Wales 2031, Australia
  • Local Institution - 0035
    St Leonards, New South Wales 2065, Australia
  • Local Institution - 0113
    South Brisbane, Queensland 4101, Australia
  • Local Institution - 0213
    Southport, Queensland 4215, Australia
  • Local Institution - 0034
    Elizabeth Vale, South Australia 5112, Australia
  • Local Institution - 0033
    Clayton, Victoria 0, Australia
  • Local Institution - 0214
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0031
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0068
    Linz, 4020, Austria
  • Local Institution - 0084
    Wien, 1160, Austria
  • Local Institution - 0058
    Gent, Oost-Vlaanderen 9000, Belgium
  • Local Institution - 0064
    Anderlecht, 1070, Belgium
  • Local Institution - 0060
    Hasselt, 3500, Belgium
  • Local Institution - 0059
    Liege, 4000, Belgium
  • Local Institution - 0047
    Brasilia, Distrito Federal 70200-730, Brazil
  • Local Institution - 0045
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0046
    Ijui, RIO Grande DO SUL 98700-000, Brazil
  • Local Institution - 0048
    Porto Alegre, RIO Grande DO SUL 90610-000, Brazil
  • Local Institution - 0043
    Barretos, Sao Paulo 14780-070, Brazil
  • Local Institution - 0044
    São Paulo, SAO Paulo 05652-900, Brazil
  • Local Institution - 0160
    Rio de Janeiro, 20775-001, Brazil
  • Local Institution - 0050
    Sao Paulo, 01246000, Brazil
  • Local Institution - 0041
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 0086
    Saint John, New Brunswick E2L 3L6, Canada
  • Local Institution - 0087
    Oshawa, Ontario L1G 2B9, Canada
  • Local Institution - 0112
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0042
    Montreal, Quebec H2X 0C1, Canada
  • Local Institution - 0040
    Rimouski, Quebec G5L 5T1, Canada
  • Local Institution - 0223
    La Serena, Coquimbo 1720430, Chile
  • Local Institution - 0246
    Santiago, Metropolitana 0, Chile
  • Local Institution
    Santiago, Metropolitana 7500713, Chile
  • Local Institution - 0221
    Santiago, Metropolitana 8420383, Chile
  • Local Institution - 0222
    Vina del Mar, Valparaiso 2520598, Chile
  • Local Institution - 0147
    Beijing, Beijing 100032, China
  • Local Institution - 0153
    Beijing, Beijing 100034, China
  • Local Institution - 0159
    Beijing, Beijing 100853, China
  • Local Institution - 0132
    Fuzhou, Fujian 350001, China
  • Local Institution - 0141
    Guangzhou, Guangdong 510120, China
  • Local Institution - 0194
    Wuhan, Hebei 430030, China
  • Local Institution - 0133
    Wuhan, Hubei 430061, China
  • Local Institution - 0138
    Nanjing, Jiangsu 210029, China
  • Local Institution - 0140
    Nanchang, Jiangxi 0, China
  • Local Institution - 0145
    Changchun, Jilin 130021, China
  • Local Institution - 0144
    Xi'an, Shan3xi 710061, China
  • Local Institution - 0146
    Yantai, Shandong 264000, China
  • Local Institution - 0137
    Shanghai, Shanghai 200025, China
  • Local Institution - 0166
    Shanghai, Shanghai 200032, China
  • Local Institution - 0152
    Shanghai, Shanghai 200040, China
  • Local Institution - 0148
    Shanghai, Shanghai 200433, China
  • Local Institution - 0142
    Chengdu, Sichuan 610041, China
  • Local Institution - 0143
    Chengdu, Sichuan 610072, China
  • Local Institution - 0175
    Tianjin, Tianjin 300222, China
  • Local Institution - 0157
    Hangzhou, Zhejiang 310009, China
  • Local Institution - 0131
    Hangzhou, Zhejiang 310014, China
  • Local Institution - 0134
    Guangzhou, 0, China
  • Local Institution - 0139
    Nanjing, 210008, China
  • Local Institution - 0176
    Shanghai, 200032, China
  • Local Institution - 0227
    Medellin, Antioquia 050034, Colombia
  • Local Institution - 0228
    Valledupar, Cesar 200001, Colombia
  • Local Institution - 0229
    Bogotá, 111511, Colombia
  • Local Institution - 0230
    Floridablanca, 0, Colombia
  • Local Institution - 0226
    Pereira, 99999, Colombia
  • Local Institution - 0094
    Hradec Kralove, 500 05, Czechia
  • Local Institution - 0025
    Olomouc, 779 00, Czechia

Showing the first 100 of 200 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Marconi L, Sun M, Beisland C, Klatte T, Ljungberg B, Stewart GD, Dabestani S, Choueiri TK, Bex A. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clin Genitourin Cancer. 2021 Apr;19(2):e92-e99. doi: 10.1016/j.clgc.2020.12.005. Epub 2021 Jan 7. PubMed 33526329 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Sep 2023, 74 months.

Results were first posted in Dec 2024, 1 year 2 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 74 months is above that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2017
First posted
May 3, 2017
StartActual
Jul 7, 2017
Primary completionActual
Sep 28, 2023
CompletionActual
Feb 1, 2024
Results first posted
Dec 18, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03138512
Responsible party
Sponsor
First posted
May 3, 2017
Start date
Jul 7, 2017
Primary completion
Sep 28, 2023
Completion
Feb 1, 2024
Results posted
Dec 18, 2024
Last update
Dec 18, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion